Open access

555 Inhibition of FOXP3 by stapled alpha-helical peptides alters Regulatory T Cell function
Katrina Hawley, Rachel Eclov, Marie Fefferman, Gregory Bird, Mathew Schnorenberg, Ravand Samaeekia, Loren Walensky, Matthew Tirrell, James LaBelle

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A336; DOI: 10.1136/jitc-2020-SITC2020.0555
559 Fostriecin potentiates genome instability and anti-tumor immunity in ovarian cancer
Remya Raja, Christopher Wu, Kristina Butler, Marion Curtis

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A337; DOI: 10.1136/jitc-2020-SITC2020.0559
561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation
Alexander Muik, Isil Altintas, Rachelle Kosoff, Friederike Gieseke, Kristina Schödel, Theodora Salcedo, Saskia Burm, Aras Toker, Lena Kranz, Mathias Vormehr, David Eisel, Mark Fereshteh, Özlem Türeci, Esther Breij, Tahamtan Ahmadi, Ugur Sahin, Maria Jure-Kunkel

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A338-A339; DOI: 10.1136/jitc-2020-SITC2020.0561
563 Pharmacodynamics and pharmacokinetics of SO-C101 in cynomolgus monkeys
Nada Podzimkova, Irena Adkins, Guy de Martynoff, David Bechard, Radek Spisek, Ulrich Moebius

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A339; DOI: 10.1136/jitc-2020-SITC2020.0563
564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents
Matthew Bernett, Rajat Varma, Ke Liu, Christine Bonzon, Rumana Rashid, Nicole Rodriguez, Nargess Hassanzadeh-Kiabi, Connie Ardila, Seung Chu, Umesh Muchhal, John Desjarlais

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A340; DOI: 10.1136/jitc-2020-SITC2020.0564
567 MDK1319/MDK-701: A potent fully efficacious peptidyl agonist of IL-7Rαγc, designed with no reference to cytokine or receptor structure and unrelated to IL-7, fused to an Fc-domain for PK enhancement
William Dower, Alice Bakker, Steven Cwirla, Prarthana Joshi, Praechompoo Pongtornpipat, Blake Williams, Sandra Wang, Michael Needels, Ronald Barrett

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A341-A342; DOI: 10.1136/jitc-2020-SITC2020.0567
572 Fibroblast activating protein (FAP)-targeting IL-12 (anti-FAP/IL-12) TMEkine™ potentiates anti-cancer effects in preclinical cancer models
Donggeon Kim, Dahea Lee, Soomin Ryu, Yeongseon Byeon, Kyoung-Ho Pyo, Jae-Hwan Kim, Seul Lee, Dong Kwon Kim, Eun Ji Lee, Seung Yeon Oh, Byoung Chul Cho, Byoung Chul Lee

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A344; DOI: 10.1136/jitc-2020-SITC2020.0572
575 Regression by hetIL-15 monotherapy in different mouse breast cancer models correlates with intratumoral infiltration of a novel population of dendritic cells
Sevasti Karaliota, Dimitris Stellas, Vasiliki Stravokefalou, Bethany Nagy, Cristina Bergamaschi, Barbara Felber, George Pavlakis

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A345-A346; DOI: 10.1136/jitc-2020-SITC2020.0575
577 Engineered non-pathogenic synthetic biotic producing L-arginine synergize with PD-1-based cancer immunotherapy
Fernando Canale, Camilla Basso, Ning Li, Anna Sokolovska, Michela Perotti, Michael James, Wenjie Jin, Jean-Philippe Theurillat, Daniel Leventhal, Kip West, Jose Lora, Federica Sallusto, Roger Geiger

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A346; DOI: 10.1136/jitc-2020-SITC2020.0577
579 Lactate dehydrogenase C-associated molecular networks predict enhanced tumor growth and impaired immune response in breast cancer
Julie Decock, Adviti Jana

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A347; DOI: 10.1136/jitc-2020-SITC2020.0579

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages